RU2720160C2 - Зажим для колпачка для иглы, крышка, автоматическое инъекционное устройство и способ изготовления зажима - Google Patents

Зажим для колпачка для иглы, крышка, автоматическое инъекционное устройство и способ изготовления зажима Download PDF

Info

Publication number: RU2720160C2
Authority: RU; Russia
Prior art keywords: holder; clamp; clip; cover; needle
Prior art date: 2015-06-03

Application number

RU2017146070A

Other languages

English (en)

Russian (ru)

Other versions

RU2017146070A3 (2

RU2017146070A (ru

Inventor

Томас Марк КЕМП

Луиз ХОДЖСОН

Джордж САЙКС

Original Assignee

Санофи-Авентис Дойчланд Гмбх

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-03

Filing date

2016-06-02

Publication date

2020-04-24

2016-06-02 Application filed by Санофи-Авентис Дойчланд Гмбх filed Critical Санофи-Авентис Дойчланд Гмбх

2019-07-09 Publication of RU2017146070A publication Critical patent/RU2017146070A/ru

2019-11-07 Publication of RU2017146070A3 publication Critical patent/RU2017146070A3/ru

2020-04-24 Application granted granted Critical

2020-04-24 Publication of RU2720160C2 publication Critical patent/RU2720160C2/ru

Links

239000007924 injection Substances 0.000 title claims abstract description 59
238000002347 injection Methods 0.000 title claims abstract description 59
238000004519 manufacturing process Methods 0.000 title claims abstract description 14
238000005452 bending Methods 0.000 claims abstract description 15
238000005520 cutting process Methods 0.000 claims abstract description 7
238000009434 installation Methods 0.000 claims description 6
229910052751 metal Inorganic materials 0.000 claims description 5
239000002184 metal Substances 0.000 claims description 5
239000000126 substance Substances 0.000 abstract description 5
230000000694 effects Effects 0.000 abstract description 2
230000000717 retained effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 description 28
229940079593 drug Drugs 0.000 description 26
230000001681 protective effect Effects 0.000 description 17
101000976075 Homo sapiens Insulin Proteins 0.000 description 16
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 15
108090000765 processed proteins & peptides Proteins 0.000 description 15
102000004196 processed proteins & peptides Human genes 0.000 description 14
229920001184 polypeptide Polymers 0.000 description 12
150000003839 salts Chemical class 0.000 description 11
239000000427 antigen Substances 0.000 description 10
102000036639 antigens Human genes 0.000 description 10
108091007433 antigens Proteins 0.000 description 10
150000001875 compounds Chemical class 0.000 description 8
239000012634 fragment Substances 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 6
238000012377 drug delivery Methods 0.000 description 6
-1 naked and cDNAs) Chemical class 0.000 description 6
239000007787 solid Substances 0.000 description 6
108010088406 Glucagon-Like Peptides Proteins 0.000 description 5
108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
238000001746 injection moulding Methods 0.000 description 5
239000000203 mixture Substances 0.000 description 5
HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 4
108010011459 Exenatide Proteins 0.000 description 4
102100024952 Protein CBFA2T1 Human genes 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
201000010099 disease Diseases 0.000 description 4
150000004676 glycans Chemical class 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
238000000034 method Methods 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
239000004033 plastic Substances 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
102000009109 Fc receptors Human genes 0.000 description 3
108010087819 Fc receptors Proteins 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
238000007792 addition Methods 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
239000003055 low molecular weight heparin Substances 0.000 description 3
229940127215 low-molecular weight heparin Drugs 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
238000003860 storage Methods 0.000 description 3
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
208000002249 Diabetes Complications Diseases 0.000 description 2
229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 2
208000005189 Embolism Diseases 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
108010019598 Liraglutide Proteins 0.000 description 2
XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
108020004459 Small interfering RNA Proteins 0.000 description 2
208000001435 Thromboembolism Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000001447 alkali salts Chemical class 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
229960001519 exenatide Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229920002674 hyaluronan Polymers 0.000 description 2
229960001093 lixisenatide Drugs 0.000 description 2
108010004367 lixisenatide Proteins 0.000 description 2
239000000463 material Substances 0.000 description 2
230000035515 penetration Effects 0.000 description 2
238000003825 pressing Methods 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000012453 solvate Substances 0.000 description 2
MSFZPBXAGPYVFD-NFBCFJMWSA-N (2r)-2-amino-3-[1-[3-[2-[2-[2-[4-[[(5s)-5,6-diamino-6-oxohexyl]amino]butylamino]-2-oxoethoxy]ethoxy]ethylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid Chemical compound NC(=O)[C@@H](N)CCCCNCCCCNC(=O)COCCOCCNC(=O)CCN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O MSFZPBXAGPYVFD-NFBCFJMWSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
125000000041 C6-C10 aryl group Chemical group 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
URRAHSMDPCMOTH-LNLFQRSKSA-N Denagliptin Chemical compound C=1C=C(F)C=CC=1C([C@H](N)C(=O)N1[C@@H](C[C@H](F)C1)C#N)C1=CC=C(F)C=C1 URRAHSMDPCMOTH-LNLFQRSKSA-N 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
102400000932 Gonadoliberin-1 Human genes 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
108010069236 Goserelin Proteins 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
108010024118 Hypothalamic Hormones Proteins 0.000 description 1
102000015611 Hypothalamic Hormones Human genes 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108010057186 Insulin Glargine Proteins 0.000 description 1
COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108010047386 Pituitary Hormones Proteins 0.000 description 1
102000006877 Pituitary Hormones Human genes 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
229920002385 Sodium hyaluronate Polymers 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
108010010056 Terlipressin Proteins 0.000 description 1
206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
229960004733 albiglutide Drugs 0.000 description 1
OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 1
229960004539 alirocumab Drugs 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940093265 berberine Drugs 0.000 description 1
YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
229940015047 chorionic gonadotropin Drugs 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000007799 cork Substances 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
229950010300 denagliptin Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
229960004281 desmopressin Drugs 0.000 description 1
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
229960005175 dulaglutide Drugs 0.000 description 1
108010005794 dulaglutide Proteins 0.000 description 1
229950003468 dupilumab Drugs 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229960000610 enoxaparin Drugs 0.000 description 1
201000001386 familial hypercholesterolemia Diseases 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960001442 gonadorelin Drugs 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
229960002913 goserelin Drugs 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
239000000960 hypophysis hormone Substances 0.000 description 1
229940043650 hypothalamic hormone Drugs 0.000 description 1
239000000601 hypothalamic hormone Substances 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229960002869 insulin glargine Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
229940098262 kynamro Drugs 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229960002701 liraglutide Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
108091060283 mipomersen Proteins 0.000 description 1
OSGPYAHSKOGBFY-KMHHXCEHSA-A mipomersen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].N1([C@H]2C[C@@H]([C@H](O2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(NC(=O)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C3=NC=NC(N)=C3N=C2)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2[C@H](O)[C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)C=C(C)C(N)=NC1=O OSGPYAHSKOGBFY-KMHHXCEHSA-A 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
239000002985 plastic film Substances 0.000 description 1
229940071643 prefilled syringe Drugs 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000009516 primary packaging Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
108700027806 rGLP-1 Proteins 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
229950006348 sarilumab Drugs 0.000 description 1
229960004937 saxagliptin Drugs 0.000 description 1
QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
108010033693 saxagliptin Proteins 0.000 description 1
108010060325 semaglutide Proteins 0.000 description 1
229950011186 semaglutide Drugs 0.000 description 1
229960004034 sitagliptin Drugs 0.000 description 1
MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940010747 sodium hyaluronate Drugs 0.000 description 1
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229960004532 somatropin Drugs 0.000 description 1
239000010959 steel Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229940036220 synvisc Drugs 0.000 description 1
WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 1
108010048573 taspoglutide Proteins 0.000 description 1
229950007151 taspoglutide Drugs 0.000 description 1
229960003813 terlipressin Drugs 0.000 description 1
BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000013598 vector Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229940007428 victoza Drugs 0.000 description 1
229960001254 vildagliptin Drugs 0.000 description 1
SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
- A61M5/3204—Needle cap remover, i.e. devices to dislodge protection cover from needle or needle hub, e.g. deshielding devices
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production

Landscapes

Health & Medical Sciences (AREA)
Vascular Medicine (AREA)
Engineering & Computer Science (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)
Catching Or Destruction (AREA)

RU2017146070A 2015-06-03 2016-06-02 Зажим для колпачка для иглы, крышка, автоматическое инъекционное устройство и способ изготовления зажима RU2720160C2 (ru)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP15170595		2015-06-03
EP15170595.1		2015-06-03
PCT/EP2016/062459 WO2016193353A1 (en)	2015-06-03	2016-06-02	Grasper for a needle sheath, cap, autoinjector and method of producing a grasper

Publications (3)

Publication Number	Publication Date
RU2017146070A RU2017146070A (ru)	2019-07-09
RU2017146070A3 RU2017146070A3 (2)	2019-11-07
RU2720160C2 true RU2720160C2 (ru)	2020-04-24

Family

ID=53365859

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2017146070A RU2720160C2 (ru)	2015-06-03	2016-06-02	Зажим для колпачка для иглы, крышка, автоматическое инъекционное устройство и способ изготовления зажима

Country Status (15)

Country	Link
US (3)	US11045610B2 (2)
EP (2)	EP4541395A3 (2)
JP (1)	JP6755891B2 (2)
KR (1)	KR102569868B1 (2)
CN (1)	CN107708770B (2)
AR (1)	AR104872A1 (2)
AU (1)	AU2016269705B2 (2)
BR (1)	BR112017025753B1 (2)
DK (1)	DK3302640T3 (2)
HK (1)	HK1249455A1 (2)
IL (1)	IL256006B (2)
MX (1)	MX2017015602A (2)
RU (1)	RU2720160C2 (2)
TW (1)	TW201707741A (2)
WO (1)	WO2016193353A1 (2)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3458131T3 (da)	2016-05-18	2022-05-23	Sanofi Aventis Deutschland	Hylsterfjerner og fremgangsmåder til samling deraf
US10583255B2 (en) *	2016-07-27	2020-03-10	Shl Medical Ag	Medicament container assembly for a medicament delivery device
US10300214B2 (en) *	2016-07-27	2019-05-28	Shl Medical Ag	Cap assembly for a medicament delivery device
CH712753A2 (de)	2016-07-28	2018-01-31	Tecpharma Licensing Ag	Trennen einer Nadelschutzkappe von einem Produktbehälter und Verfahren zum Montieren einer Injektionsvorrichtung.
EP3490647B1 (de) *	2016-07-28	2021-10-06	Ypsomed AG	Injektionsvorrichtung mit äusserer kappe mit nadelschutzkappenentfernerelement und verfahren zum montieren einer injektionsvorrichtung
ES2870497T3 (es) *	2017-06-02	2021-10-27	Becton Dickinson France	Extractor de tapa de inyector médico
US10828425B2 (en) *	2017-06-23	2020-11-10	Shl Medical Ag	Needle shield remover and a medicament delivery device comprising the needle shield remover
CN111163819A (zh)	2017-10-12	2020-05-15	伊莱利利公司	用于药物递送系统的针护罩拉拔器
KR102384109B1 (ko)	2017-11-07	2022-04-08	에스에이치엘 메디컬 아게	바늘 쉴드 제거기 및 바늘 쉴드 제거기를 포함하는 약물 전달 장치
CN111372634A (zh) *	2017-11-23	2020-07-03	赛诺菲	用于移除和保持针护罩的设备
EP3574945B1 (en) *	2018-05-31	2024-07-10	Aspen Global Incorporated	Protective device comprising a protective cover with fixed claws
USD932006S1 (en)	2018-11-21	2021-09-28	Regeneron Pharmaceuticals, Inc.	Auto-injector cap
EP3666314A1 (en) *	2018-12-10	2020-06-17	Ares Trading S.A.	Injection device
WO2020173998A1 (en) *	2019-02-26	2020-09-03	Becton Dickinson France	Rigid needle shield remover for autoinjector
CN113474025B (zh)	2019-02-26	2023-12-01	贝克顿迪金森法国公司	具有声频指示器的自动注射器
KR102615193B1 (ko) *	2019-02-26	2023-12-19	벡톤 디킨슨 프랑스	자동 주사 장치를 위한 낙하 테스트 특징부를 구비한 강성 바늘 쉴드 분리기
CN113490521B (zh)	2019-02-26	2023-05-02	贝克顿迪金森法国公司	带有帽的自动注射器
CH714525A2 (de) *	2019-03-28	2019-06-28	Tecpharma Licensing Ag	Injektionsvorrichtung mit einer Kappe zur Entfernung einer Nadelschutzkappe von einem Produktbehälter und Verfahren zum Montieren einer Injektionsvorrichtung.
WO2021041067A2 (en) *	2019-08-23	2021-03-04	Amgen Inc.	Drug delivery device with configurable needle shield engagement components and related methods
IL291004B1 (en)	2019-09-30	2026-04-01	Amgen Inc	Drug delivery device
EP4090398A1 (en)	2020-01-13	2022-11-23	Amgen Inc.	Needle shield removers, drug delivery devices, and related methods
CN115916302B (zh) *	2020-07-01	2026-01-16	赛诺菲	针罩移除组件、其组装方法和药物递送装置
IL312187A (en)	2021-10-20	2024-06-01	Regeneron Pharma	Methods for treating prurigo nodularis by administering an IL-4R antagonist
GB2613642A (en) *	2021-12-13	2023-06-14	Owen Mumford Ltd	A needle shield remover
US20230220089A1 (en)	2021-12-30	2023-07-13	Regeneron Pharmaceuticals, Inc.	Methods for attenuating atopic march by administering an il-4/il-13 antagonist
IL316264A (en)	2022-05-02	2024-12-01	Regeneron Pharma	Antibody formulations against interleukin-4 receptor (IL-4R)
US20240117021A1 (en)	2022-06-15	2024-04-11	Bioverativ Usa Inc.	Anti-complement c1s antibody formulation
CA3260415A1 (en)	2022-06-24	2023-12-28	Bioverativ Usa Inc.	METHODS OF TREATMENT FOR COMPLEMENT-MEDICATED DISEASES
KR20250037491A (ko)	2022-07-08	2025-03-17	리제너론 파아마슈티컬스, 인크.	Il-4r 길항제 투여에 의한 소아 호산구성 식도염을 치료하는 방법
CN120476001A (zh)	2022-10-31	2025-08-12	赛诺菲	用于药物递送装置的前子组件
EP4611855A1 (en)	2022-10-31	2025-09-10	Sanofi	Audible indicator, indicator holder and method of assembling an audible indicator
EP4611848A1 (en)	2022-10-31	2025-09-10	Sanofi	Device body for a drug delivery device, assembly for a drug delivery device and drug delivery device
EP4611846A1 (en)	2022-10-31	2025-09-10	Sanofi	Plunger for expelling a drug, drug delivery device, rear sub-assembly and corresponding methods
CN120500361A (zh)	2022-10-31	2025-08-15	赛诺菲	具有反馈元件的药物递送装置以及用于向药物递送装置的用户提供关于剂量分配过程的反馈的方法
EP4611854A1 (en)	2022-10-31	2025-09-10	Sanofi	Drug delivery device having a two-part user indicator
WO2024094704A1 (en)	2022-10-31	2024-05-10	Sanofi	Arrangement for a drug delivery device, drug delivery device and method for assembly
EP4611853A1 (en)	2022-10-31	2025-09-10	Sanofi	Assembly for a drug delivery device
WO2024094699A1 (en)	2022-10-31	2024-05-10	Sanofi	Container holder and drug delivery device comprising the container holder
WO2024094700A1 (en)	2022-10-31	2024-05-10	Sanofi	Method for assembling an assembly for a drug delivery device and drug delivery device.
CN120187754A (zh)	2022-11-01	2025-06-20	瑞泽恩制药公司	通过施用il-4r拮抗剂治疗手足皮炎的方法
JP2025541690A (ja)	2022-11-23	2025-12-23	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	Ｉｌ－４ｒアンタゴニストを投与することによる、骨成長を改善するための方法
AU2024241290A1 (en)	2023-03-22	2025-11-06	Regeneron Pharmaceuticals, Inc.	Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
EP4688142A1 (en)	2023-03-27	2026-02-11	Regeneron Pharmaceuticals, Inc.	Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonist
KR20260010767A (ko)	2023-04-14	2026-01-21	키맵 리미티드	항-ox40l 항체를 함유하는 약학적 제형
CN121816187A (zh)	2023-09-15	2026-04-07	建新公司	用非妥西兰治疗血友病a
WO2025162927A1 (en)	2024-01-29	2025-08-07	Sanofi	Purifying device, system and method for purifying a needle for delivering a medicament
WO2025162926A1 (en)	2024-01-29	2025-08-07	Sanofi	Needle arrangement, drug delivery device comprising the needle arrangement and method for operating the drug delivery device
WO2025162928A1 (en)	2024-01-29	2025-08-07	Sanofi	Needle shroud unlock device for a medicament delivery device
WO2025171279A1 (en)	2024-02-09	2025-08-14	Genzyme Corporation	Treatment of hemophilia with fitusiran
WO2025212516A1 (en)	2024-04-01	2025-10-09	Genzyme Corporation	Treatment of factor x deficiency with fitusiran
US20250388685A1 (en)	2024-04-15	2025-12-25	Sanofi Biotechnology	Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
WO2026055687A1 (en)	2024-09-09	2026-03-12	Regeneron Pharmaceuticals, Inc.	Methods for treating bullous pemphigoid by administering an il-4r antagonist
WO2026059949A1 (en)	2024-09-10	2026-03-19	Sanofi Biotechnology	Methods for treating chronic pruritus of unknown origin (cpuo) by administering an il-4r antagonist

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070112310A1 (en) *	2003-07-31	2007-05-17	Sid Technologies Llc	Injecting apparatus
WO2009081103A1 (en) *	2007-12-20	2009-07-02	Ucb Pharma S.A.	Auto- injector with a syringe lock for locking the barrel coupling element and syringe coupled thereto in said retract position
RU2009102986A (ru) *	2006-06-30	2010-08-10	Эбботт Байотекнолоджи Лтд. (Bm)	Автоматическое инъекционное устройство
EP2361648A1 (en) *	2010-02-18	2011-08-31	Sanofi-Aventis Deutschland GmbH	Remover for a protective needle shield

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH09285542A (ja) *	1996-04-22	1997-11-04	Takemasa Doumori	注射針の誤剌防止用クリップ
GB2438590B (en) *	2006-06-01	2011-02-09	Cilag Gmbh Int	Injection device
GB0625169D0 (en) *	2006-12-18	2007-01-24	Medical House Plc The	Improved autoinjector
DK2240222T3 (en)	2008-01-11	2018-06-25	Ucb Biopharma Sprl	SYSTEMS FOR THE ADMINISTRATION OF PHARMACEUTICALS FOR PATIENTS WITH RHEUMATOID ARTHRITIS
SMT201900652T1 (it) *	2008-07-18	2020-01-14	Ucb Biopharma Sprl	Sistemi per somministrare medicinale per pazienti con artrite reumatoide
AU2010226442A1 (en) *	2009-03-20	2011-10-13	Antares Pharma, Inc.	Hazardous agent injection system
AR076466A1 (es)	2010-04-27	2011-06-15	Kelly Jose Luis	Sistema y proceso de potabilizacion de agua, a traves del medio ambiente y/o de agua obtenida de red municipal o colectiva, y/o de agua obtenida de pozo, y/o de agua obtenida en recipientes domesticos e industriales
US20120022937A1 (en)	2010-07-22	2012-01-26	Yahoo! Inc.	Advertisement brand engagement value
UA112308C2 (uk) *	2011-01-24	2016-08-25	Еббві Байотекнолоджи Лтд.	Знімання кожухів голки зі шприців і автоматичних ін'єкційних пристроїв
EP2489380A1 (en) *	2011-02-18	2012-08-22	Sanofi-Aventis Deutschland GmbH	Injection device
EP2489383A1 (en) *	2011-02-18	2012-08-22	Sanofi-Aventis Deutschland GmbH	Auto-injector
BR112013032839B1 (pt)	2011-06-22	2021-08-03	Fresenius Medical Care Deutschland Gmbh	Clínica de diálise com rede de emissão zero, clínica médica e método para implementação de um prédio com rede de emissão zero
CA2851245C (en)	2011-10-07	2019-11-26	Home Dialysis Plus, Ltd.	Heat exchange fluid purification for dialysis system
BR112014009229A8 (pt) *	2011-10-17	2017-06-20	Shl Group Ab	dispositivo para remover protetores de membro de dispensação
EP2583705A1 (en)	2011-10-21	2013-04-24	Sanofi-Aventis Deutschland GmbH	Indicator arrangement for an auto-injector
EP2596823A1 (en)	2011-11-24	2013-05-29	Sanofi-Aventis Deutschland GmbH	Autoinjector
EP2596826A1 (en) *	2011-11-24	2013-05-29	Sanofi-Aventis Deutschland GmbH	Safety syringe
DK2978478T3 (da)	2013-03-25	2021-08-02	Shl Medical Ag	Beskyttelseshætte til en medikamentafgivelsesanordning
EP2823836A1 (en) *	2013-07-09	2015-01-14	Sanofi-Aventis Deutschland GmbH	Autoinjector
EP2823838A1 (en) *	2013-07-09	2015-01-14	Sanofi-Aventis Deutschland GmbH	Autoinjector
EP2823841A1 (en) *	2013-07-09	2015-01-14	Sanofi-Aventis Deutschland GmbH	Autoinjector
WO2016132187A1 (en)	2015-02-19	2016-08-25	Renalyx Health Systems Pvt Ltd	A portable regenerative haemodialysis system and a method thereof

2016
- 2016-06-01 TW TW105117157A patent/TW201707741A/zh unknown
- 2016-06-02 AR ARP160101626A patent/AR104872A1/es unknown
- 2016-06-02 US US15/579,144 patent/US11045610B2/en active Active
- 2016-06-02 CN CN201680032188.5A patent/CN107708770B/zh active Active
- 2016-06-02 RU RU2017146070A patent/RU2720160C2/ru active
- 2016-06-02 AU AU2016269705A patent/AU2016269705B2/en active Active
- 2016-06-02 HK HK18107996.9A patent/HK1249455A1/zh unknown
- 2016-06-02 EP EP24223535.6A patent/EP4541395A3/en active Pending
- 2016-06-02 JP JP2017562584A patent/JP6755891B2/ja active Active
- 2016-06-02 EP EP16727462.0A patent/EP3302640B1/en active Active
- 2016-06-02 MX MX2017015602A patent/MX2017015602A/es unknown
- 2016-06-02 BR BR112017025753-0A patent/BR112017025753B1/pt active IP Right Grant
- 2016-06-02 DK DK16727462.0T patent/DK3302640T3/da active
- 2016-06-02 WO PCT/EP2016/062459 patent/WO2016193353A1/en not_active Ceased
- 2016-06-02 KR KR1020177037817A patent/KR102569868B1/ko active Active
2017
- 2017-11-30 IL IL256006A patent/IL256006B/en unknown
2021
- 2021-06-11 US US17/345,720 patent/US12357770B2/en active Active
2025
- 2025-01-14 US US19/020,052 patent/US20250152839A1/en active Pending

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070112310A1 (en) *	2003-07-31	2007-05-17	Sid Technologies Llc	Injecting apparatus
RU2009102986A (ru) *	2006-06-30	2010-08-10	Эбботт Байотекнолоджи Лтд. (Bm)	Автоматическое инъекционное устройство
WO2009081103A1 (en) *	2007-12-20	2009-07-02	Ucb Pharma S.A.	Auto- injector with a syringe lock for locking the barrel coupling element and syringe coupled thereto in said retract position
EP2361648A1 (en) *	2010-02-18	2011-08-31	Sanofi-Aventis Deutschland GmbH	Remover for a protective needle shield

Also Published As

Publication number	Publication date
KR20180015677A (ko)	2018-02-13
EP3302640A1 (en)	2018-04-11
US11045610B2 (en)	2021-06-29
KR102569868B1 (ko)	2023-08-24
EP4541395A2 (en)	2025-04-23
EP3302640B1 (en)	2025-02-12
CN107708770A (zh)	2018-02-16
IL256006B (en)	2021-12-01
TW201707741A (zh)	2017-03-01
EP4541395A3 (en)	2025-05-14
RU2017146070A3 (2)	2019-11-07
WO2016193353A1 (en)	2016-12-08
AU2016269705B2 (en)	2020-10-22
CN107708770B (zh)	2021-02-26
JP2018520738A (ja)	2018-08-02
US12357770B2 (en)	2025-07-15
IL256006A (en)	2018-01-31
RU2017146070A (ru)	2019-07-09
US20210338940A1 (en)	2021-11-04
DK3302640T3 (da)	2025-05-05
AR104872A1 (es)	2017-08-23
JP6755891B2 (ja)	2020-09-16
AU2016269705A1 (en)	2018-01-18
US20250152839A1 (en)	2025-05-15
HK1249455A1 (zh)	2018-11-02
US20180133407A1 (en)	2018-05-17
BR112017025753A2 (pt)	2018-08-14
BR112017025753B1 (pt)	2022-11-22
MX2017015602A (es)	2018-04-30

Publication	Publication Date	Title
RU2720160C2 (ru)	2020-04-24	Зажим для колпачка для иглы, крышка, автоматическое инъекционное устройство и способ изготовления зажима
RU2720168C2 (ru)	2020-04-24	Держатель шприца и автоматическое инъекционное устройство
RU2719957C2 (ru)	2020-04-23	Фиксатор кожуха
RU2719022C2 (ru)	2020-04-16	Шприцедержатель для автоматического инъекционного устройства и способ его сборки
RU2719917C2 (ru)	2020-04-23	Устройство доставки лекарственного средства
CN107750175B (zh)	2020-11-27	药物输送装置
CN111315429B (zh)	2022-08-09	柱塞和药物输送装置
TW201705994A (zh)	2017-02-16	自動注射器及組裝方法
CN107735125B (zh)	2020-08-28	易于刺穿药筒的药物输送装置
TW201729859A (zh)	2017-09-01	用於注射裝置之帽蓋
CN108601902B (zh)	2021-07-02	具有帽的药物输送装置
CN108495678A (zh)	2018-09-04	注射装置
CN114602007A (zh)	2022-06-10	注射器支架和自动注射器
CN109641109B (zh)	2022-06-03	听觉指示器
CN108367124A (zh)	2018-08-03	注射装置
CN108290011A (zh)	2018-07-17	具有针护罩移除机构的注射装置
CN107750176A (zh)	2018-03-02	用于覆盖针罩的盖组件以及用于装配盖组件的方法
EP3484556B1 (en)	2023-07-05	Drug delivery device with controlled needle shield and cover sleeve
CN108495674A (zh)	2018-09-04	注射装置
HK40001471B (en)	2024-02-16	Drug delivery device with controlled needle shield and cover sleeve
HK40001471A (en)	2020-02-28	Drug delivery device with controlled needle shield and cover sleeve